Crocus sativus L. — it takes 150,000 flowers and 400 hours of hand-picking to produce 1 kg of saffron. In BIORYA, we don't use raw saffron, but a standardized Moodreal extract — the same reproducible batch quality from one cure to the next, titrated on the two key markers: safranal and crocins.
1. Botanical identity card
2. Active compounds — the 4 molecules that matter
Crocins
Glycosylated water-soluble carotenoids — unique to saffron. Responsible for the color and most of the antioxidant activity (Ahmadi 2020).
Safranal
Monoterpene aldehyde. Anxiolytic and sedative effect via GABA-A receptors and partial NMDA antagonism (Hosseinzadeh 2009).
Crocetin
Aglycone form of crocins. Crosses the blood-brain barrier — it's the one that reaches the CNS. Documented neuroprotective action (Yoshino 2011).
Picrocrocin
Bitter glycoside, precursor of safranal. Quality marker — its presence guarantees saffron authenticity (ISO 3632 standard).
3. Mechanism of action — a multi-target pharmacological profile
Unlike classic antidepressant medications that target a single pathway, saffron acts simultaneously on multiple systems. That explains its safety profile and its studied efficacy:
- Serotonin reuptake inhibition — SSRI-like mechanism, validated in vitro at 67% Moodreal activity vs imipramine reference.
- Increase in dopamine and norepinephrine — modulates the motivation / vigilance axis (Hosseinzadeh 2010).
- GABAergic modulation — safranal binds to GABA-A receptors and supports a calmed state without marked sedative effect.
- NMDA antagonism — reduces glutamatergic excitotoxicity linked to chronic stress.
- Neural anti-inflammatory action — ↓ TNF-α and IL-6 in preclinical models (Yoshino 2011).
- Antioxidant activity — crocins neutralize ROS from cerebral oxidative stress.
The 67% activity result comes from an in vitro model (serotonin reuptake test vs imipramine as reference). The Natac brochure states that above 50%, the effect is judged significant in this model. Useful to understand the "how" — but the real test remains human clinical trials, below.
4. Human clinical trials — 3 comparative studies
Three randomized double-blind trials (6 weeks, Hamilton Depression Rating Scale / HAM-D) measure saffron's efficacy against placebo and against two reference antidepressants:
Saffron vs Placebo
Population · 40 adults
Dose · 30 mg/day (15 mg × 2)
Duration · 6 weeks
HAM-D result · −53 % vs −22 %
Significance · p < 0.001
Saffron vs Fluoxetine
Population · 40 adults
Comparator · Fluoxetine 20 mg/day
Duration · 6 weeks
HAM-D result · −54 % vs −64 %
Conclusion · comparable efficacy (p < 0.001)
Saffron vs Imipramine
Population · 30 adults
Comparator · Imipramine 100 mg/day
Duration · 6 weeks
HAM-D result · −54 % vs −55 %
Conclusion · comparable efficacy (p < 0.001)
Important reading: these trials were conducted in adults with mild to moderate depression. In the BIORYA context, saffron does not treat a pathology — it supports day-to-day emotional stability, at an equivalent dose.
5. Meta-analyses and level of evidence
6. Effective dosing
| Goal | Validated dose | Onset time |
|---|---|---|
| Emotional balance support | 28–30 mg/day | 2–4 weeks |
| HAM-D clinical studies | 30 mg/day (15 mg × 2) | 4–6 weeks |
| Studied therapeutic range | 15–100 mg/day | — |
| Acute toxicity (mouse LD50) | ≈ 20 g/kg | safety margin ≈ 600× |
In CALM AUTHORITY, Moodreal saffron is dosed at 30 mg / 2 capsules (including 0.6 mg of safranal) — exactly the dose of the clinical trials cited above.
7. Why BIORYA chose Moodreal
The saffron market is saturated with non-standardized extracts whose active content can vary 1 to 10× from one batch to another. Moodreal — developed by Natac (Spanish lab specialized in botanical extraction) — solves this by guaranteeing a reproducible level of safranal and crocins, batch after batch. It's the biochemical consistency that makes the effect predictable.
In the formula, saffron brings the emotional balance dimension — where L-theanine soothes and Rhodiola rebuilds resilience, saffron stabilizes the baseline mood. Combined with the 60-second ritual and the 30-day journal, it fits into a measurable and reproducible logic.
8. Cited studies
- Akhondzadeh S. et al. (2005). Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial. BMC Complementary and Alternative Medicine.
- Noorbala A. A. et al. (2005). Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. Journal of Ethnopharmacology.
- Akhondzadeh S. et al. (2005). Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytotherapy Research.
- Hausenblas H. A. et al. (2013). Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. Journal of Integrative Medicine.
- Tóth B. et al. (2019). The efficacy of saffron in the treatment of mild to moderate depression: a meta-analysis. Planta Medica.
- Hosseinzadeh H., Sadeghnia H. R. (2009). Safranal, a constituent of Crocus sativus, attenuates effect of NMDA-induced excitotoxicity. Pharmacological Research.
- Yoshino F. et al. (2011). Effects of crocetin on inflammatory responses in human lymphocytes. Journal of Functional Foods.
- Ahmadi M. et al. (2020). Crocin and saffron: a review on the antioxidant, anti-inflammatory and neuroprotective effects. Phytotherapy Research.
- Natac (R&D Brochure). Moodreal® — Standardized Saffron Extract: efficacy and mechanism documentation.
Ready to add Moodreal saffron to your daily ritual?